Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Arog Pharmaceuticals, Inc.
Arog Pharmaceuticals, Inc.
Children's Oncology Group
Medical College of Wisconsin
Therapeutic Advances in Childhood Leukemia Consortium
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Barbara Ann Karmanos Cancer Institute
Washington University School of Medicine
Washington University School of Medicine
Washington University School of Medicine